Innate Pharma SA

Innate Pharma S.A. is a biotechnology company that develops immunotherapies for cancer patients. The company operates in France and internationally. Its product pipeline includes Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for cutaneous T-cell and peripheral T-cell lymphoma. Innate Pharma also develops IPH4502, a topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4, and Monalizumab, a dual checkpoint inhibitor that targets T Cells and NK Cells. Further pipeline candidates include IPH5201, a blocking antibody in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway; IPH6401, a BCMA-targeting NK cell engager; IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, a B7-H3-targeting NK cell engager. Additionally, the company develops IPH6501, a tetra-specific NK cell engager designed to activate receptors NKp46 and CD16, tumor antigen (CD20), and an interleukin-2 receptor. Innate Pharma S.A. has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech. The company was incorporated in 1999 and is based in Marseille, France.